GlobeNewswire

New Study Finds Nearly Half of Women Seeking Help for Menstrual Symptoms Say Their Concerns Were Dismissed
04/11/2026
Global Clue study of almost 12,000 people reveals widespread menstrual health challenges, with one in three who sought medical care told their symptoms were normal or not a problem. BERLIN, Nov. 04, 2026 (GLOBE NEWSWIRE [...]
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
04/11/2026
New analyses further characterize the clinical activity and approved dosing regimen of RYTELO® (imetelstat) in lower-risk MDS FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a [...]
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
04/11/2026
The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology (ASH) Annual Meeting [...]
SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
04/11/2026
− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients with relapsed/ [...]
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
04/11/2026
– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax’s scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia [...]
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
04/11/2026
Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site [...]
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
04/11/2026
New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off [...]
Kamau Therapeutics Announces First Multi-Patient Clinical Data Showing Precise Correction of the Sickle Cell Mutation and Restoration of Adult Hemoglobin
04/11/2026
All three patients are transfusion-independent with no vaso-occlusive events; predominant adult hemoglobin profile restored, with sickle hemoglobin below 20% beyond six months Data to be featured in an oral presentation [...]
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
04/11/2026
WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that [...]
Atavistik Bio to Highlight Momentum Across Hematology Pipeline with Harmony-HHT Clinical Trial Update and New Preclinical Data from HHT and JAK2 V617F Programs at ASH 2026
04/11/2026
Harmony-HHT trial-in-progress poster to showcase the ongoing Phase 1/2 clinical study of ATV-1601, an investigational oral, AKT1-selective allosteric inhibitor targeting the underlying disease biology of hereditary [...]
Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting
04/11/2026
Presentations span UB-VV400 and UB-VV410 clinical data from investigator-initiated trials and trial-in-progress posters for UB-VV400 and UB-VV500 SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja [...]
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
04/11/2026
Media Release COPENHAGEN, Denmark; November 4, 2026 Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy Six [...]
Secura Bio Announces Two Duvelisib Presentations on Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma at the 2026 American Society of Hematology Annual Meeting
04/11/2026
Phase 2 PRIMO sub-analysis highlights outcomes with duvelisib in patients with peripheral T-cell lymphoma who proceeded to stem cell transplant Novel topical formulation of duvelisib in cutaneous T-cell lymphoma [...]
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
04/11/2026
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety [...]
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in- [...]
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
04/11/2026
Preclinical data supporting CITY-TFR2 for anemia of chronic disease to be presented in a poster session CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage [...]
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
04/11/2026
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in [...]
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
04/11/2026
14 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show durable [...]
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
04/11/2026
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1 [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum